nuv-868 as monotherapy and in combination with olaparib or enzalutamide in adult patients with advanced solid tumors

Conditions: Advanced Solid Tumor; Ovarian Cancer; Ovary Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasm; Pancreatic Cancer; Pancreas Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Neoplasm; Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Castrate Resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Castration Resistant Prostatic Neoplasms; Triple-negative Breast Cancer; Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; Breast Cancer; Breast Carcinoma; Cancer of Breast; Cancer of the Breast; Breast Tumor

Summary: nuv-868-01 is a first-in human, open- label, phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. the phase 1 and 1b portions include patients with advanced solid tumors and are designed to determine the safety and the dose(s) of nuv-868 to be used as monotherapy and in combination with olaparib or enzalutamide for the phase 2 portion. in phase 2, nuv-868 in combination with olaparib or enzalutamide will be given to determine the safety and efficacy of these study treatments. one cohort of patients (with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either nuv-868 monotherapy, enzalutamide monotherapy, or the combination of nuv-868 + enzalutamide. patients will self-administer nuv-868 orally daily in 28-day cycles as monotherapy in phases 1 and 2. in phases 1b and 2, patients will self-administer nuv-868 orally daily in 28-day cycles in combination with olaparib or enzalutamide daily at standard prescribed doses (phase 1b) or at the recommended phase 2 combination dose (rp2cd) that is determined in phase 1b. patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.


Eligibility criteria:
key inclusion criteria for all phases and cohorts: 1. recovered from toxicity to prior anticancer therapy 2. adequate bone marrow and organ function 3. no known active or symptomatic central nervous system (cns) disease cohort-specific inclusion criteria: in addition to the inclusion criteria listed above, the following criteria apply for enrollment into specific cohorts. phase 1 (nuv-868 monotherapy) 1. patients with advanced solid tumors that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available 2. life expectancy of \> 3 months 3. eastern cooperative oncology group performance status ≤ 2 4. measurable or non-measurable disease phase 1b (nuv-868 in combination with enzalutamide or olaparib) 1. life expectancy of \> 3 months 2. eastern cooperative oncology group performance status ≤ 2 3. (select cohorts only) measurable disease 4. patient must be able to read and write sufficiently to document food intake and study drug dosing on the dosing diary or must have a caregiver who is willing and able to complete the dosing diary with the patient. 5. one of the following tumor types: 1. ovarian: platinum-resistant or platinum-refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting 2. pancreatic: pancreatic ductal adenocarcinoma (pdac) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting 3. prostate: histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one nht in the metastatic setting 4. breast: triple-negative breast cancer (tnbc) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting 5. other advanced tumors (only phase 1b dose escalation, nuv-868 + olaparib): the study medical monitor must approve enrollment. 6. for all tumor types: patients will be allowed in the study regardless of their brca/hrr status. phase 2 1. life expectancy of \> 6 months 2. (select cohorts only): at least one measurable lesion defined by standard criteria 3. eastern cooperative oncology group performance status ≤ 1 4. one of the following tumor types: 1. ovarian: platinum-resistant or platinum- refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting 2. pancreatic: progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting 3. prostate: histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one nht in the metastatic setting 4. breast: tnbc with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting key exclusion criteria for all phases and cohorts: 1. have received chemotherapy, hormonal therapy (except for ongoing luteinizing hormone-releasing hormone \[lhrh\] analogs in male patients and premenopausal women), radiation, or biological anticancer therapy within 14 days prior to the first dose of nuv-868. 2. received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent, or within 21 days or \< 5 half-lives (whichever is longer) for myelosuppressive agent, prior to the first dose of study treatment. 3. requires medications that are known to be strong (or moderate for olaparib) inducers and/or strong (or moderate for olaparib) inhibitors of cyp3a4/5 enzymes. 4. female patients who are pregnant of breastfeeding.

Keywords: phase 1 phase 2 nuv-868 olaparib enzalutamide xtandi ovarian cancer pancreatic cancer metastatic castration-resistant prostate cancer triple-negative breast cancer lynparza parp inhibitor bet inhibitor brca mutation brca1 brca2 hrd hrr deficiency homologous recombination deficiency